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Introduction
Mycobacterium tuberculosis and its close genetic relative Mycobacterium marinum require their type VII secretion system ESX-1 (ESAT-6 Secretion System 1) for virulence (1) (2) (3) .
ESX-1 was first identified as a virulence determinant when it was shown that a 9.4 kb deletion (ΔRD1) in its locus was the primary cause of attenuation for the live attenuated vaccine BCG (1, (3) (4) (5) (6) . ESX-1 is required for multiple stages of infection in both M. tuberculosis and M. marinum, with mutants attenuated in intramacrophage growth (2, 7) , phagosomal permeabilization (8, 9) , and granuloma formation (2, 10) .
In vitro, ESX-1 mediates membrane disruption of infected lung epithelial cells (11) , cultured macrophages (11) , and red blood cells (RBCs) (12) (13) (14) . Previously, ESX-1 membranolytic activity had been ascribed to its secreted substrate ESAT-6 forming pores in host membranes (11, 13, 15) . In 2017, we found that the pore-forming activity ascribed to ESAT-6 was due to residual detergent contamination of ESAT-6 preparations (16) . Moreover, we found that ESX-1 membrane disruption was exclusively contact-dependent and caused gross membrane disruptions as opposed to distinct pores (16) .
In this paper, we report studies that began with our speculation that ESX-1 might mediate membrane disruptions through peroxidation of host membrane lipids. To test this hypothesis, we screened antioxidants for their ability to inhibit M. marinum's contact-dependent hemolytic activity and identified the clinical compound ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) as an inhibitor of ESX-1 mediated hemolysis. However, we found that ebselen inhibited hemolysis independent of its antioxidant activity, through inhibition of ESX-1dependent secretion. We showed its target to be the ESX-1 AAA+ (ATPases Associated with various cellular Activities) ATPase EccA1, the activity of which it inhibited through covalent modification of a critical cysteine residue.
Results

Ebselen inhibits ESX-1 secretion in M. marinum and M. tuberculosis
To test the hypothesis that ESX-1-dependent membrane disruptions could occur through peroxidation of host lipids, we screened antioxidants for their ability to inhibit M. marinum's contact-dependent hemolytic activity. Of the three tested, only ebselen inhibited M. marinum's hemolytic activity with a half maximal inhibitory concentration (IC50) of 9.3 µM ( Fig. 1A) . These findings indicated that ebselen's effects on RBC hemolysis was independent of its antioxidant effect, suggesting that lipid peroxidation was not the mechanism behind ESX-1 membrane disruption.
We pursued how ebselen might inhibit hemolysis independent of its antioxidant effect.
As ebselen has been reported to have antimicrobial activities against M. tuberculosis (17) , we set to determine if bacterial killing was responsible for ebselen's effect on M. marinum's hemolytic activity. We plated M. marinum that had been exposed to ebselen for the duration of the hemolysis assay and found that even the highest concentration used, 62.5 µM, did not affect viability ( Fig. 1A and 1B ). Ebselen's drug-like activities are mediated through its selenium moiety, which enables it to covalently modify free thiols, such as free cysteine residues (18, 19) .
Consistent with this, we found that an ebselen analog lacking the selenium moiety, 2-(2,6dimethylphenyl)-1-isoindolinone (DIME) failed to inhibit hemolysis ( Fig. 1C and D). Because ebselen inhibited ESX-1-dependent hemolysis (14, 16) , we asked if its primary action was on ESX-1 secretion. ESX-1 substrates are secreted in a mutually dependent manner (20, 21) , so we measured the secretion of two substrates, ESAT-6 and CFP-10, as a proxy for overall ESX-1 secretion. Ebselen treatment inhibited both ESAT-6 and CFP-10 secretion, while DIME had no effect ( Fig. 1E ).
We (16) . Ebselen exhibited similar dose-dependent inhibition of sRBC hemolysis by this ESX-1 complemented strain (ΔRD1::ESX-1Mtb) and wildtype M. marinum (Fig. 1F ). To determine if ebselen also inhibits ESX-1 secretion in M. tuberculosis, we used M. tuberculosis mc 2 6206, which is auxotrophic for leucine and pantothenic acid but retains an intact ESX-1 locus (22) . Ebselen treatment also reduced ESAT-6 secretion in M. tuberculosis ( Fig 1G) . Altogether, these results show that ebselen inhibits ESX-1 secretion in M. marinum and M. tuberculosis and suggest that the inhibition is through cysteine modification.
Ebselen inhibits M. tuberculosis EccA1 ATPase activity and covalently modifies its cysteine residues
Ebselen has been shown to inhibit the activity of prokaryotic and eukaryotic enzymes, including the yeast plasma membrane H+-ATPase (23) . These inhibitory functions occur through ebselen's reactivity with free thiols, including free cysteine residues (19) . ESX-1mediated secretion is dependent on two ATPases within the locus: the FtsK/SpoIIIE ATPase EccC1, encoded by the adjacent genes EccCa1 and EccCb1, which powers the transport of ESX-1 substrates (7, 24, 25) , and the AAA+ ATPase EccA1, which is thought to act as a chaperone for ESX-1 substrates (20, 24, 26) . Both enzymes contain multiple free cysteines, making them potential targets for ebselen. The ATPase activity of purified M. tuberculosis EccA1 protein has been demonstrated (27) whereas there are no published data on the activity of purified M. tuberculosis EccC1. We attempted to purify both EccA1 and EccC1 (as an EccCa1/Cb1 fusion) and only succeeded in purifying EccA1. We found that ebselen inhibited the ATPase activity of purified EccA1 in a dose-dependent manner, starting at 1µM and plateauing at 8µM with an IC50 of 2.5 µM ( Fig. 2A ).
To determine if ebselen's inhibition of EccA1 was due to covalent cysteine modification, mass spectrometry analyses were performed on the ebselen-treated aliquots in Fig. 2A .
Analysis of tryptic peptides from these samples revealed ebselen modification of cysteines 204 and 531. Representative MS/MS spectra of these peptides from the 8 μM ebselen treatment are depicted for Cys204 and Cys531 ( Fig. 2B and 2C ). We found that these modifications occurred in a two-step manner: at ebselen concentrations up to 4 μM we observed only Cys204 ebselenmodified peptides, and at higher concentrations we observed ebselen-modified peptides for both Cys204 and Cys531 ( Fig 2D) . Based on this result, we hypothesized that ebselen's inhibition of EccA1 was a two-step process, where ebselen modification of Cys204 and Cys531 each contributed to inhibition of ATPase activity. If so, the inhibition curve would incorporate two curves, reflecting the contribution of each modification. We fit two logistic functions to the curve: a two curve model corresponding to a two-step inhibition (full model) or a single-curve model corresponding to a single step inhibition (reduced model) ( Fig S1) , and we found that the twocurve model was a better fit (p=0.021, nested model F-test), supporting the hypothesis that ebselen inhibition of EccA1 was a two-step process.
EccA1 Cys204 is located in a hydrophobic pocket essential for ATPase activity
In addition to the ATPase domain that mediates EccA1's assembly and enzymatic activity (27) , EccA1 has a large N-terminal domain that is comprised of six tetratricopeptide repeat (TPR) motifs and a β-finger insert (28) , and this domain is dispensable for its in vitro ATPase activity (27) . As TPR motifs mediate protein-protein interactions (29) , this domain is predicted to mediate the EccA1 chaperone's substrate recognition (28) . Of the two residues modified by ebselen, Cys531 is located in the C-terminal ATPase domain whereas Cys204 is within N-terminal TPR domain (Fig. 3A) . The modification of Cys531 provides an obvious explanation for ebselen's inhibitory effect. However, we found that Ebselen's binding to Cys204
was also linked to inhibition of activity, suggesting that conservation of the TPR domain is required for full-length EccA1's ATPase activity. The two-step inhibition curve along with the MS analysis of ebselen-treated EccA1 indicated that ebselen modification of Cys204 preceded that of Cys531. Moreover, sequence alignment revealed that of the two cysteine residues, only Cys204 is conserved across mycobacterial EccA1 homologs (Fig. 3B) , and while M. marinum EccA1 lacks Cys531, yet ESX-1 secretion was inhibited by ebselen. These results suggested that Ebselen's binding to EccA1 Cys204 mediates in substantial measure its inhibition of ESX-1 secretion.
Examination of the crystal structure of EccA1's TPR domain (PDB: 4F3V) revealed that Cys204 is located in the TPR domain's hydrophobic core ( Fig. 3C ) (28) . To confirm Cys204's role in ebselen's activity, we engineered an EccA1 where the Cys204 had been changed to a valine (EccA1 C204V) or to the more hydrophilic residue serine (EccA1 C204S). We saw that EccA1 C204V had similar ATPase activity to the wildtype enzyme ( Fig. 3D ), while EccA1 C204S was showed only 14% of wildtype EccA1 (Fig. 3F ). These findings suggested that while Cys204 is dispensable for enzymatic activity, conservation of its hydrophobic environment is essential for EccA1's ATPase function.
Ebselen allosterically inhibits EccA1 through modification of Cys204
If ebselen's ATPase inhibitory activity was primarily due to modification of Cys204, then EccA1 C204V should not be inhibited by ebselen treatment. When we treated both wildtype and EccA1 C204V with ebselen, we found modification of EccA1 Cys204 was essential for ebselen inhibition: when treated with 8 μM ebselen, EccA1 C204V retained 95% of its ATPase activity vs ~60% for WT EccA1 (Fig. 3F Cys204 is essential for ebselen's allosteric inhibition of EccA1 ATPase activity.
Discussion
In searching for the mechanism of mycobacterial ESX-1-mediated membrane disruption, Ebselen has been demonstrated to be clinically safe and well tolerated in humans (38), suggesting its use an anti-virulence drug complement to standard anti-tuberculous chemotherapy. It is currently undergoing clinical trials for preventing aminoglycoside-induced ototoxicity (NCT: 02819856). Aminoglycosides remain essential components of MDR-TB treatment, but cause difficult to predict ototoxicity leading to hearing loss (39) . Ebselen's potential otoprotective and anti-virulence properties may combine to make it particularly attractive in aminoglycoside containing tuberculosis treatment regimens.
Materials and Methods
Bacterial strains and methods Strains used are listed in Supplementary Table 2 . All M.
marinum strains were derived from wild-type M. marinum purchased from American Type Culture Collection (strain M, ATCC #BAA-535). Wildtype and ∆RD1::ESX-1Mtb strains were generated and maintained as described previously (16) . M. tuberculosis mc 2 6206 was cultured in 7H9 complete media containing 0.05% tween 80 supplemented with pantothenic acid (12 μg/mL) and leucine (25 μg /mL).
Hemolysis assay
Hemolytic activity was assessed as described previously (16) . Briefly, 100 µL of sheep red blood cells (sRBCs) were transferred to each condition and 100 µL of PBS or bacterial suspension were added on top and incubated for two hours at 33°C. 100% lysis with 0.1% Tx100 (Sigma). Drugs stocks were made at 200x concentrations and 0.5% DMSO was used as a vehicle control.
Secretion Assays Secretion assays were conducted as described previously with minor modifications (16 
Purification of EccA1
Purification constructs were expressed in E. coli C43 (DE3) (Lucigen). 
